|
|
| Line 1: |
Line 1: |
| {{DISPLAYTITLE:}}
| | 처음에는 가볍게 한 번 받아볼까 하는 생각으로 시작했다가 이후로 꾸준히 찾게 되는 경우도 많습니다. <br><br>부산출장안마의 가장 큰 특징은 시간 맞춰 편하게 받을 수 있다는 점입니다. 굳이 나갈 필요 없이 숙소나 집에서 받을 수 있기 때문에 이 부분에서 만족도가 높은 편입니다. <br><br>다만 경험이 없는 상태라면 막연하게 검색만 하게 되는 경우가 많습니다. <br><br>보통 검색을 통해 정보를 보게 되는데 이 부분에서 이미 차이가 많이 납니다. 내용이 비슷하게 반복되는지 정도만 봐도 대략적인 판단은 가능합니다. <br><br>가격도 중요한 요소 중 하나입니다. 적당한 수준인지 확인하는 것이 좋습니다. 가격만 보지 않는 게 중요합니다. <br><br>또 하나 중요한 건 예약 과정입니다. 문의했을 때 답변이 어떤지 이런 부분에서 업체의 운영 방식이 보입니다. <br><br>[https://busantherapyy.imweb.me/ 부산출장안마]는 단순히 서비스를 받는 개념이 아니라. 그래서 무조건 유명한 곳보다는 맞는 곳이 중요합니다. <br><br>결론적으로 여러 정보를 보고 판단하는 것이 좋습니다. 간단하게 비교해보고 선택해도 충분히 만족할 수 있습니다. |
| __NOTOC__
| |
| <!-- Hides title of Main Page via CSS (see PART B) -->
| |
| <div class="neoplasm-title-wrapper">
| |
| Neoplasm.org – An Open Hematology/Oncology Reference
| |
| </div> | |
| <div class="neoplasm-center neoplasm-hero-subtitle"> | |
| <small>Neoplasm.org is a collaborative, open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens.
| |
| Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.</small>
| |
| | |
| {| class="wikitable neoplasm-table neoplasm-table--quicklinks"
| |
| |-
| |
| | colspan="2" class="neoplasm-table-title" | Quick links to major topic areas
| |
| |-
| |
| | class="neoplasm-chip neoplasm-chip--solid" | [[#solidtumors|Solid Tumors]]
| |
| | class="neoplasm-chip neoplasm-chip--malignant" | [[#malignantheme|Malignant Hematology]]
| |
| |}
| |
| | |
| ==Links to all main disease pages==
| |
| <span id="solidtumors"></span> | |
| | |
| {| class="wikitable neoplasm-table neoplasm-table--grid"
| |
| |-
| |
| ! colspan="4" class="neoplasm-major neoplasm-major--solid" | '''Solid Tumors'''
| |
| |-
| |
| | colspan="4" class="neoplasm-minor neoplasm-minor--solid" | '''Breast Oncology'''
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Early breast cancer (EBC)'''
| |
| |-
| |
| | class="neoplasm-cell" | [[Early breast cancer|EBC, NOS]]
| |
| | class="neoplasm-cell" | [[Early breast cancer, HR-positive|HR-positive EBC]]
| |
| | class="neoplasm-cell" | [[Early breast cancer, HER2-positive|HER2-positive EBC]]
| |
| | class="neoplasm-cell" | [[Early breast cancer, HER2-low|HER2-low EBC]]
| |
| |-
| |
| | class="neoplasm-cell" | [[Early breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive EBC]]
| |
| | class="neoplasm-cell" | [[Early breast cancer, triple negative|Early triple-negative breast cancer (eTNBC)]]
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Metastatic breast cancer (MBC)'''
| |
| |-
| |
| | class="neoplasm-cell" | [[Metastatic breast cancer|MBC, NOS]]
| |
| | class="neoplasm-cell" | [[Metastatic breast cancer, HR-positive|HR-positive MBC]]
| |
| | class="neoplasm-cell" | [[Metastatic breast cancer, HER2-positive|HER2-positive MBC]]
| |
| | class="neoplasm-cell" | [[Metastatic breast cancer, HER2-low|HER2-low MBC]]
| |
| |-
| |
| | class="neoplasm-cell" | [[Metastatic breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive MBC]]
| |
| | class="neoplasm-cell" | [[Metastatic breast cancer, triple negative|Metastatic triple-negative breast cancer (mTNBC)]]
| |
| | class="neoplasm-cell" | [[Breast cancer, CNS metastases|CNS metastases]]
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Breast cancer with molecular alterations'''
| |
| |-
| |
| | class="neoplasm-cell" | [[Breast cancer, BRCA-mutated|BRCA-mutated Breast cancer]]
| |
| | class="neoplasm-cell" | [[Metastatic breast cancer, PI3K pathway-altered|PI3K pathway-altered Breast cancer]]
| |
| |-
| |
| | colspan="4" class="neoplasm-minor neoplasm-minor--solid" | '''Dermatologic Oncology'''
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Melanoma'''
| |
| |-
| |
| | class="neoplasm-cell" | [[Melanoma|Melanoma, NOS]]
| |
| | class="neoplasm-cell" | [[Melanoma,_BRAF-mutated|BRAF-mutated Melanoma]]
| |
| | class="neoplasm-cell" | [[Melanoma,_KIT-mutated|KIT-mutated Melanoma]]
| |
| | class="neoplasm-cell" | [[Melanoma,_NRAS-mutated|NRAS-mutated Melanoma]]
| |
| |-
| |
| | class="neoplasm-cell" | [[Uveal melanoma]]
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Non-melanoma skin cancer (NMSC)'''
| |
| |-
| |
| | class="neoplasm-cell" | [[Cutaneous basal cell carcinoma|Cutaneous BCC]]
| |
| | class="neoplasm-cell" | [[Cutaneous squamous cell carcinoma|Cutaneous SCC]]
| |
| | class="neoplasm-cell" | [[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]]
| |
| |-
| |
| | colspan="4" class="neoplasm-minor neoplasm-minor--solid" | '''Endocrine Oncology'''
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Other endocrine cancers'''
| |
| |-
| |
| | class="neoplasm-cell" | [[Adrenocortical carcinoma]]
| |
| | class="neoplasm-cell" | [[Neuroendocrine tumor|Neuroendocrine tumor (NET)]]
| |
| | class="neoplasm-cell" | [[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]]
| |
| | class="neoplasm-cell" | [[Pancreatic NET]]
| |
| |-
| |
| | class="neoplasm-cell" | [[Pheochromocytoma]]
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Thyroid cancer without molecular alterations'''
| |
| |-
| |
| | class="neoplasm-cell" | [[Thyroid cancer|Thyroid cancer, NOS]]
| |
| | class="neoplasm-cell" | [[Thyroid cancer, anaplastic|Anaplastic thyroid cancer (ATC)]]
| |
| | class="neoplasm-cell" | [[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]]
| |
| | class="neoplasm-cell" | [[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]]
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Thyroid cancer with molecular alterations'''
| |
| |-
| |
| | class="neoplasm-cell" | [[Thyroid_cancer,_BRAF-mutated|BRAF-mutated Thyroid cancer]]
| |
| | class="neoplasm-cell" | [[Thyroid_cancer,_RET-positive|RET-positive Thyroid cancer]]
| |
| |-
| |
| | colspan="4" class="neoplasm-minor neoplasm-minor--solid" | '''Gastrointestinal Oncology'''
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Upper GI tract'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Esophageal cancer|Esophageal cancer, NOS]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Esophageal adenocarcinoma]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Esophageal squamous cell carcinoma|Esophageal squamous cell carcinoma (ESCC)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Gastric cancer|Gastric cancer, NOS]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Gastric cancer, HER2-positive|HER2-positive gastric cancer]]
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Lower GI tract'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Anal cancer]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Appendiceal tumor]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Colon cancer|Colon cancer, NOS]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Colon cancer, RAS wild-type|RAS wild-type colon cancer]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer|Colorectal cancer (CRC), NOS]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer, BRAF-mutated|BRAF-mutated CRC]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer, HER2-positive|HER2-positive CRC]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer, MSI-H or dMMR|MSI-H or dMMR CRC]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Colorectal cancer, RAS wild-type|RAS wild-type CRC]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Rectal cancer]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Small bowel adenocarcinoma]]
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Hepatobiliary cancer'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Biliary tract cancer]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Cholangiocarcinoma]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Gallbladder cancer]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Periampullary adenocarcinoma]]
| |
| |-
| |
| | colspan="4" class="neoplasm-sub" | '''Pancreatic cancer'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Pancreatic cancer|Pancreatic adenocarcinoma, NOS]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Pancreatic cancer, BRCA-mutated|BRCA-mutated Pancreatic adenocarcinoma]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Pancreatic cancer, NRG1-positive|NRG1-positive Pancreatic adenocarcinoma]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Pancreatic NET]]
| |
| |-
| |
| |}
| |
| | |
| | |
| <span id="malignantheme"></span> | |
| | |
| {| class="wikitable neoplasm-table"
| |
| |-
| |
| | colspan="4" class="neoplasm-major neoplasm-major--heme" | '''Malignant Hematology'''
| |
| |-
| |
| | colspan="4" class="neoplasm-subheader" | '''Acute leukemias'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Acute leukemia, KMT2A-rearranged]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Acute myeloid leukemia|Acute myeloid leukemia (AML)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Acute myeloid leukemia, FLT3-positive|AML, FLT3-positive]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Acute myeloid leukemia, IDH-mutated|AML, IDH-mutated]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Acute myeloid leukemia, NPM1-mutated|AML, NPM1-mutated]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Acute promyelocytic leukemia|Acute promyelocytic leukemia (APL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[B-cell acute lymphoblastic leukemia|B-cell acute lymphoblastic leukemia (B-ALL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[B-cell acute lymphoblastic leukemia, Ph-positive|B-ALL, Ph+]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[T-cell acute lymphoblastic leukemia|T-cell acute lymphoblastic leukemia (T-ALL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[CNS leukemia]]
| |
| |-
| |
| | colspan="4" class="neoplasm-subheader" | '''Myeloproliferative neoplasms and myelodysplastic syndromes'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Chronic myeloid leukemia|Chronic myeloid leukemia (CML)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Chronic myelomonocytic leukemia|Chronic myelomonocytic leukemia (CMML)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Essential thrombocythemia|Essential thrombocythemia (ET)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Hypereosinophilic syndrome|Hypereosinophilic syndrome (HES)]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Myelofibrosis|Primary & secondary myelofibrosis (PMF/SMF)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Myeloproliferative neoplasm, accelerated phase|Myeloproliferative neoplasm, accelerated phase (MPN-AP)]] <span class="neoplasm-new">New</span>
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Polycythemia vera|Polycythemia vera (PV)]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Systemic mastocytosis]]
| |
| |-
| |
| | colspan="4" class="neoplasm-subheader" | '''Aggressive lymphomas'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Burkitt lymphoma|Burkitt lymphoma (BL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[CNS lymphoma]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Diffuse large B-cell lymphoma, gastric|Gastric DLBCL]] <span class="neoplasm-new">New</span>
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[High-grade B-cell lymphoma|High-grade B-cell lymphoma (HGBL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[HIV-associated lymphoma]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Transformed lymphoma|Transformed lymphoma (TL)]]
| |
| |-
| |
| | colspan="4" class="neoplasm-subheader" | '''Indolent lymphomas'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Chronic lymphocytic leukemia|Chronic lymphocytic leukemia (CLL/SLL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Follicular lymphoma|Follicular lymphoma (FL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Hodgkin lymphoma, nodular lymphocyte-predominant|NLP-HL]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Indolent lymphoma|Indolent lymphoma (iNHL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[B-cell lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
| |
| |-
| |
| | colspan="4" class="neoplasm-subheader" | '''Plasma cell dyscrasias'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Light-chain (AL) amyloidosis]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Multiple myeloma|Multiple myeloma (main page)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Multiple myeloma, induction|MM induction]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Multiple myeloma, consolidation and maintenance|MM consolidation & maintenance]]
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Multiple myeloma, relapsed-refractory|MM relapsed/refractory]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Plasma cell leukemia|Plasma cell leukemia (PCL)]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[POEMS syndrome]]
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]
| |
| |-
| |
| | colspan="4" class="neoplasm-subheader" | '''Disease-agnostic'''
| |
| |-
| |
| | class="neoplasm-cell neoplasm-cell--w25" | [[Malignant hematologic neoplasm, FGFR1-mutated|FGFR1]] <span class="neoplasm-new">New</span>
| |
| |}
| |
| | |
| | |
| <div class="neoplasm-center neoplasm-footer-link">'''[[Special:AllPages|Browse our complete index of pages]]'''</div>
| |
| | |
| ==Additional Information==
| |
| Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes [[how to contribute|continuous peer review]].
| |
| | |
| Any information that one feels would be helpful to other oncology providers is welcome. Visit [[how to contribute]] for more details.
| |
| | |
| Priorities of this project include:
| |
| <section begin=goals /> | |
| *'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
| |
| *'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature.
| |
| *'''[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
| |
| *'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
| |
| *'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
| |
| <section end=goals /> | |
| | |
| Additional possibilities for this project may include:
| |
| *Creating synopses of pivotal clinical trials and regimens
| |
| *Prioritizing regimens by their efficacy and/or toxicity
| |
| *Capturing historical regimens that were standard-of-care prior to 2005
| |
| *Checklists for common clinical scenarios/diseases
| |
| *Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
| |
| | |
| The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [https://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
| |
| | |
| <br><inputbox> | |
| type=create
| |
| width=70
| |
| placeholder=Type the name of the page you want to create
| |
| break=no
| |
| </inputbox>
| |
